Genetic variants of CYP19 (aromatase) and breast cancer risk

被引:146
作者
Kristensen, VN
Harada, N
Yoshimura, N
Haraldsen, E
Lonning, P
Erikstein, B
Kåresen, R
Kristensen, T
Borresen-Dale, AL [1 ]
机构
[1] Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway
[2] Fujita Hlth Univ, Sch Med, Dept Biochem, Toyoake, Aichi 47011, Japan
[3] Norwegian Radium Hosp, Inst Canc Res, Dept Oncol, N-0310 Oslo, Norway
[4] Univ Bergen, Haukeland Hosp, Dept Oncol, N-5020 Bergen, Norway
[5] Univ Oslo, Ullevaal Hosp, Dept Oncol, N-0407 Oslo, Norway
[6] Univ Oslo, Dept Biochem, N-0316 Oslo, Norway
关键词
CYP19 (aromatase); estrogen metabolism; polymorphism; breast cancer risk;
D O I
10.1038/sj.onc.1203425
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of a SNP in exon 10 of CYP19 on tumor mRNA levels and splice variants were studied and correlated with clinical parameters and risk of breast cancer. In the vast majority of breast cancers, the estrogen levels modulate the tumor growth and depend on the activity of CYP19, Patients (n=481) and controls (n=236) were genotyped by T-tracks in a single sequencing reaction (SSR), The frequency of TT genotypes was significantly higher in patients versus controls (P=0.007) particularly among those with stage III and IV disease (P=0.004) and with tumors larger than 5 cm (P=0.001), A significant association between presence of the T allele and the level of aromatase mRNA in the tumors was observed (P=0.018), as well as with a switch from adipose promoter to ovary promoter (P=0.004). Previously, we reported a rare polymorphic allele of CYP19 (repeat (TTTA)(12)) to be significantly more frequent in breast cancer patients than in controls, Here we describe another polymorphism, a C-T substitution in exon 10 of the CYP19 gene which is in strong linkage disequilibrium with the (TTTA)n polymorphism but with higher frequency of the variant allele, Our data suggest that the T-allele of the CYP19 gene is associated with a 'high activity' phenotype.
引用
收藏
页码:1329 / 1333
页数:5
相关论文
共 19 条
[1]   Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase [J].
Burak, WE ;
Quinn, AL ;
Farrar, WB ;
Brueggemeier, RW .
BREAST CANCER RESEARCH AND TREATMENT, 1997, 44 (01) :57-64
[2]   STRUCTURE OF THE INT-5, A NOVEL MMTV INTEGRATION GENOMIC LOCUS CONTAINING MOUSE EARLY TRANSPOSON LTR HOMOLOGY REGION [J].
DURGAM, VR ;
EASTON, JA ;
SURYA, R ;
TEKMAL, RR .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1995, 1263 (01) :89-92
[3]   Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene [J].
Fisher, CR ;
Graves, KH ;
Parlow, AF ;
Simpson, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6965-6970
[4]   Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women [J].
Hankinson, SE ;
Willett, WC ;
Manson, JE ;
Colditz, GA ;
Hunter, DJ ;
Spiegelman, D ;
Barbieri, RL ;
Speizer, FE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (17) :1292-1299
[5]   TISSUE-SPECIFIC EXPRESSION OF THE HUMAN AROMATASE CYTOCHROME-P-450 GENE BY ALTERNATIVE USE OF MULTIPLE EXONS-1 AND PROMOTERS, AND SWITCHING OF TISSUE-SPECIFIC EXONS-1 IN CARCINOGENESIS [J].
HARADA, N ;
UTSUMI, T ;
TAKAGI, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11312-11316
[6]  
HARADA N, 1992, AM J HUM GENET, V51, P666
[7]  
HARADA N, 1995, PHARMACOGENETICS, V5, P59
[8]   High-throughput screening for known mutations by automated analysis of single sequencing reactions [J].
Kristensen, T ;
Kristensen, VN ;
Borresen-Dale, AL .
BIOTECHNIQUES, 1998, 24 (05) :832-835
[9]   A rare CYP19 (aromatase) variant may increase the risk of breast cancer [J].
Kristensen, VN ;
Andersen, TI ;
Lindblom, A ;
Erikstein, B ;
Magnus, P ;
Borresen-Dale, AL .
PHARMACOGENETICS, 1998, 8 (01) :43-48
[10]  
MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463